Exploring the Efficacy and Implications of GLP-1 Drugs

With the rise of GLP-1 receptor agonists, often referred to as GLP-1s, these medications have recently captured significant attention within the medical community and broader cultural conversations. Most people are likely familiar with the catchy Ozempic jingle, showcasing this drug's integration into popular discourse. This month's edition presents a comprehensive overview of the numerous studies being published in prominent peer-reviewed journals, although only a fraction of the available research is covered here. The continuous release of findings underscores the ongoing relevance and intrigue surrounding this class of medications.

In her piece “Compare and Contrast,” Kelly Horvath delves into the cardiac implications for individuals using these obesity management treatments. Conversations with various researchers provide new insights into how this class of pharmaceuticals may influence heart health. Rozalina G. McCoy, MD, MS, from the University of Maryland's School of Public Health THRIVE Lab, and Stacey M. Sklepinski, MD, from Advocate Lutheran General Hospital, emphasize the need to discern whether any cardiovascular advantages linked to GLP-1 receptor agonists extend beyond improvements tied to glycemic control or weight loss. Current indirect evidence from cardiovascular outcome trials suggests that these heart health benefits may be partially independent of glucose reduction, though the impact of weight loss was not similarly analyzed.

In “Beyond the Scale: What Else Glucagon-like Peptide-1 Receptor Agonists Can Do,” Horvath evaluates various studies examining the broader effects of incretin-based therapies. These studies explore not only cardiovascular health improvements but also impacts on liver function, quality of life, and insulin resistance, among other areas. Ambarish Pandey, MD, MSCS, from the University of Texas Southwestern Medical Center in Dallas, advises clinicians against hesitancy in prescribing semaglutide to patients who may seem too fragile due to obesity-related heart failure with preserved ejection fraction (HFpEF). He notes that these vulnerable patients often benefit most from the treatment: "In our analysis, the frailest patients experienced the largest symptom improvements, a greater likelihood of enhanced frailty status, and fewer serious adverse events when treated with semaglutide compared to placebo. If your previous reservations were due to concerns about a patient's robustness, reconsider; these are precisely the individuals who should be receiving this therapy."

Shifting focus, Endocrine News Senior Editor Derek Bagley discusses recent findings related to side effects in “Side Effects.” This analysis considers both the advantageous and adverse unintended consequences of GLP-1 receptor agonists. Positively, these drugs have been associated with decreased consumption of alcohol and drugs, as well as reduced compulsions related to sex and gambling. Conversely, some rare but fatal complications have been identified, which endocrinologists must remain vigilant about. Eli J. Louwagie, MD, PhD, from the Department of Internal Medicine at LewisGale Hospital Montgomery in Virginia emphasizes the necessity of identifying all possible risks, particularly infrequent ones, to mitigate the potential for negative outcomes. This call for caution becomes even more pressing as the usage of these medications continues to rise within the population.

Additionally, Derek pays tribute to Joel Habener, MD, who passed away in December at the age of 88. His contributions have undeniably influenced the development and understanding of GLP-1s and other drugs aimed at combating obesity. Daniel J. Drucker, MD, a senior investigator at Lunenfeld-Tanenbaum Research Institute and a professor within the University of Toronto's Department of Medicine, describes Habener as a groundbreaking scientist whose discoveries have fundamentally changed the field of metabolic medicine. He is remembered not only for his innovations but as a dedicated mentor to many who went on to become independent investigators themselves.

As we look forward to more research and evolving insights, readers are encouraged to participate in ongoing discussions. If you have any story suggestions that might interest members of the Endocrine Society, feel free to reach out at: mnewman@endocrine.org.

The piece titled “Miracle Drugs or Too Good to Be True?” aims to provide a balanced view of the efficacy and implications surrounding these powerful medications in ongoing therapeutic discussions.